论文部分内容阅读
作者测定了急性髓细胞白血病(AML)72例老年患者血清乳酸脱氢酶(LDH)活性,评价了该活性在临床转归中的预后价值。 材料与方法 72例初治患者,男性43例,女性29例;年龄60～79岁,中位年龄67岁。AML为原发或继发于骨髓增生异常综合征(MDS)(其中急性早幼粒细胞白血病因应用诱导分化治疗而未包括在本研究中),均用强烈的化疗方案治疗。诱导缓解治疗由去甲氧基柔红霉素(IDA)+阿糖胞苷(Ara—c)组成。如获部份缓解(PR),采用第二个相同的疗程。在获得完全缓解(CR)后。用诱导期相同的药物+鬼臼乙叉甙巩固
The authors measured serum lactate dehydrogenase (LDH) activity in 72 elderly patients with acute myeloid leukemia (AML) and evaluated the prognostic value of this activity in clinical outcomes. Materials and Methods 72 patients were initially treated, 43 males and 29 females; aged 60-79 years, median age 67 years. AML is either primary or secondary to myelodysplastic syndromes (MDS), in which acute promyelocytic leukemia is not included in this study because of the application of differentiation-inducing therapy and is treated with a strong chemotherapy regimen. Induced remission therapy consisted of idarubicin (IDA) + cytarabine (Ara-c). If partial remission (PR) is achieved, use the second same course of treatment. After getting complete remission (CR). With the same induction period of the drug + Epinephrine Consolidation